AU769279B2 - U4, a member of the hematopoietin receptor superfamily - Google Patents

Description

WO 99/53066 PCT/US99/07882 U4, A MEMBER OF THE HEMATOPOIETIN RECEPTOR SUPERFAMILY This application is a continuation-in-part of application Ser. No.

08/784,863, filed January 16, 1997.

Field of the Invention The present invention relates to new members of the mammalian hematopoietin superfamily of proteins (including without limitation human and murine receptor proteins), fragments thereof and recombinant polynucleotides and cells useful for expressing such proteins.

Background of the Invention A variety of regulatory molecules, known as hematopoietins, have been identified which are involved in the development and proliferation of the various populations of hematopoietic or blood cells. Most hematopoietins exhibits certain biological activities by interacting with a receptor on the surface of target cells.

Cytokine receptors are commonly composed of one, two or three chains. Many cytokine receptors and some cytokines, such as IL-12 p 4 0, are members of the hematopoietin receptor superfamily of proteins. Identification of new members of the hematopoietin receptor superfamily can be useful in regulation of hematopoiesis, in regulation of immune responses and in identification of other members of the hematopoietin superfamily, including cytokines and receptors.

It would be desirable to identify and determine the DNA and protein sequence for heretofore unknown members of the hematopoietin receptor superfamily.

Summary of the Invention In accordance with the present invention, polynucleotides encoding the U4 hematopoietin receptor superfamily chain are disclosed, including without limitation those from the murine and human sources. In certain embodiments, the invention provides an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: the nucleotide sequence of SEQ ID NO:4 from nucleotide 242 to nucleotide 1396; WO 99/53066 PCT/US99/07882 the nucleotide sequence of SEQ ID NO:6 from nucleotide 71 to nucleotide 1225; the nucleotide sequence of SEQ ID NO:9 from nucleotide 136 to nucleotide 1401; a nucleotide sequence varying from the sequence of the nucleotide sequence specified in or as a result of degeneracy of the genetic code; a nucleotide sequence capable of hybridizing under stringent conditions to the nucleotide specified in or a nucleotide sequence encoding a species homologue of the sequence specified in or and an allelic variant of the nucleotide sequence specified in or Preferably, the nucleotide sequence encodes a protein having a biological activity of the U4 hematopoietin receptor superfamily chain. The nucleotide sequence may be operably linked to an expression control sequence. In preferred embodiments, the polynucleotide comprises the nucleotide sequence of SEQ ID NO:4 from nucleotide 242 to nucleotide 1396; the nucleotide sequence of SEQ ID NO:4 from nucleotide 122 to nucleotide 1396; the nucleotide sequence of SEQ ID NO:6 from nucleotide 71 to nucleotide 1225; or the nucleotide sequence of SEQ ID NO:6 from nucleotide 11 to nucleotide 1225; or the nucleotide sequence of SEQ ID NO:9 from nucleotide 136 to nucleotide 1401; or the nucleotide sequence of SEQ ID NO:9 from nucleotide 247 to nucleotide 1401.

The invention also provides isolated polynucleotides comprising a nucleotide sequence encoding a peptide or protein comprising an amino acid sequence selected from the group consisting of: the amino acid sequence of SEQ ID the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425; the amino acid sequence of SEQ ID NO:7; the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408; WO 99/53066 PCT/US99/07882 the amino acid sequence of SEQ ID NO: the amino acid sequence of SEQ ID NO: 10 from amino acids 38 to 421; and fragments of having a biological activity of the U4 hematopoietin receptor superfamily chain.

Other preferred embodiments encode the amino acid sequence of SEQ ID the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425; the amino acid sequence of SEQ ID NO:7; the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408; the amino acid sequence of SEQ ID NO: 10; and the amino acid sequence of SEQ ID NO: 10 from amino acids 38 to 421.

Host cells, preferably mammalian cells, transformed with the polynucleotides are also provided.

In other embodiments, the invention provides a process for producing a U4 protein. The process comprises: growing a culture of the host cell of the present invention in a suitable culture medium; and purifying the human U4 protein from the culture.

Proteins produced according to these methods are also provided.

The present invention also provides for an isolated U4 protein comprising an amino acid sequence selected from the group consisting of: the amino acid sequence of SEQ ID the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425; the amino acid sequence of SEQ ID NO:7; the amino acid sequence of SEQ ID NO:7 from amino acids 24 to 408; and fragments of having a biological activity of the U4 hematopoietin receptor superfamily chain.

Preferably the protein comprises the amino acid sequence of SEQ ID NO:5; the amino acid sequence of SEQ ID NO:5 from amino acids 41 to 425; the amino acid sequence of SEQ ID NO:7; or the amino acid sequence of SEQ ID NO:7 from 11/11 '03 08:43 FAX 61 3 9663 3099 FB RICE CO. 004 4 amino acids 24 to 408. In other preferred embodiments, the specified amino acid sequence is part of a fusion protein (with an additional amino acid sequence not derived from U4). Preferred fusion proteins comprise an antibody fragment, such as an Fc fragment.

Pharmaceutical compositions comprising a protein of the present invention and a pharmaceutically acceptable carrier are also provided.

The present invention further provides for compositions comprising an antibody which specifically reacts with a protein of the present invention.

The present invention provides an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: the nucleotide sequence SEQ ID NO:9 from nucleotide 136 to nucleotide 1401; a nucleotide sequence varying form the sequence of the nucleotide sequence specified in as a result of degeneracy; and an allelic variant of the nucleotide sequence specified in The present invention provides the amino acid sequence of SEQ ID NO: Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated S. 25 element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Detailed Description of Preferred Embodiments The inventors of the present application have for the first time identified and provided polynucleotides encoding the U4 hematopoietin receptor superfamily chain (hereinafter "U4" or "U4 protein"), including without limitation polynucleotides encoding murine and human U4.

V.

A 79 amino acid region of the human IL-5 receptor

^(LMTNAFISIIDLSKYDVQVRAAVSSMCREAGLWSEWSQPIYVGNDEHIPLRE

oee *o••oo *~o COMS ID No: SMBI-00488587 Received by IP Australia: Time 09:43 Date 2003-11-11 WFVIVIMATICFILLIL, SEQ ID NO:1) was used to search the GenBank EST database using the TBLASTN algorithm. EST W66776 was identified with homology to this region, suggesting that this might encode a novel hematopoietin receptor.

Translation of the reverse-complement of this EST using the GCG map program revealed a protein sequence in the second reading frame that contained the conserved WSXWS motif found in hematopoietin receptors. However, a stop codon was also present in this reading frame at nucleotide 227, indicating that this EST either was not a novel hematopoietin receptor, or that the DNA sequence in the EST was incorrect.

To determine whether this EST sequence might be related to a hematopoietin receptor, we screened a murine embryo library with an oligonucleotide probe of the sequence CTTGGCTTGG AAGAGGAAAT CCTTGAGAGC (SEQ ID NO:2). A full-length cDNA clone U6-3(1A) was identified and complete sequence was obtained.

The DNA sequence and the predicted amino acid sequence for the murine protein are reported as SEQ ID NO:4

S

WO 99/53066 PCT/US99/07882 and SEQ ID NO:5, respectively. The murine protein encodes a novel member of the hematopoietin receptor family. It has a leader sequence, and the conserved cysteine pairs, PP, and WSXWS motifs characteristic of this family. This clone has no transmembrane or cytoplasmic domains. Alignment of this clone with the EST in GenBank revealed that the EST did have a frame shift mutation.

SEQ ID NO:4 provides the nucleotide sequence of a cDNA encoding the murine U4. SEQ ID NO:5 provides predicted the amino acid sequence of the receptor chain, including a putative signal sequence from amino acids 1-40. The mature murine U4 is believed to have the sequence of amino acids 41-383 of SEQ ID To identify additional related sequences in GenBank, the W66776 sequence was used to search GenBank using the BLASTN algorithm. A closely related EST, H14009, derived from human genomic DNA was identified. An oligonucleotide derived from this EST CTGAGCGTGC GCTGGGTGTC GCCAC (SEQ ID NO:3) was then used to isolate a cDNA clone from a human cDNA library. A cDNA clone (HU4-3B) encoding a full-length mature protein homolog was completely sequenced. This clone does not have a complete signal sequence, but does encode the entire predicted full-length mature protein. The human clone is homologous at the DNA level with the mouse clone. The predicted amino acid sequences have 95% identity between human and mouse. The nucleotide and amino acid sequence for human U4 are reported as SEQ ID NO:6 and SEQ ID NO:7, respectively.

SEQ ID NO:6 provides the nucleotide sequence of a cDNA encoding the human U4. SEQ ID NO:7 provides predicted the amino acid sequence of the receptor chain, including a putative signal sequence from amino acids 1-23. The mature human U4 is believed to have the sequence of amino acids 24-380 of SEQ ID NO:7.

The murine and human clones were deposited with the American Type Culture Collection on January 15, 1997, as accession numbers ATCC 98305 and ATCC 98306, respectively.

WO 99/53066 PCT/US99/07882 Human U4 protein can be expressed by replacing the human leader sequence with the sequence of the murine leader, or by extending the human leader sequence with amino acids 1-14 of the murine sequence (MPAGRPGPVA QSAR, SEQ ID NO:8). Additionally, a longer cDNA or genomic clone encoding the actual human leader can be isolated using the sequences disclosed herein as probes.

The sequence of the human U4 cDNA described above was used to isolate a longer cDNA encoding human U4 protein. The nucleotide sequence of this longer clone is reported in SEQ ID NO:9. The predicted amino acid sequence encoded thereby is reported in SEQ ID NO:10. The longer cDNA clone was deposited with the American Type Culture Collection on March 10, 1998, as accession number ATCC 98688.

Any forms of U4 proteins of less than full length are encompassed within the present invention and are referred to herein collectively with full length and mature forms as "U4" or "U4 proteins." U4 proteins of less than full length may be produced by expressing a corresponding fragment of the polynucleotide encoding the full-length U4 protein (SEQ ID NO:4 or SEQ ID NO:6). These corresponding polynucleotide fragments are also part of the present invention.

Modified polynucleotides as described above may be made by standard molecular biology techniques, including construction of appropriate desired deletion mutants, site-directed mutagenesis methods or by the polymerase chain reaction using appropriate oligonucleotide primers.

For the purposes of the present invention, a protein has "a biological activity of the U4 hematopoietin receptor superfamily chain" if it possess one or more of the biological activities of the corresponding mature U4 protein.

U4 or active fragments thereof (U4 proteins) may be fused to carrier molecules such as immunoglobulins. For example, soluble forms of the U4 may be fused through "linker" sequences to the Fc portion of an immunoglobulin. Other fusions proteins, such as those with GST, Lex-A or MBP, may also be used.

The invention also encompasses allelic variants of the nucleotide sequences as set forth in SEQ ID NO:4 or SEQ ID NO:6, that is, naturally-occurring alternative forms of the isolated polynucleotide of SEQ ID NO:4 or SEQ ID NO:6 WO 99/53066 PCT/US99/07882 which also encode U4 proteins, preferably those proteins having a biological activity of U4. Also included in the invention are isolated polynucleotides which hybridize to the nucleotide sequence set forth in SEQ ID NO:4 or SEQ ID NO:6 under highly stringent conditions (for example, O.lxSSC at 65 0 Isolated polynucleotides which encode U4 proteins but which differ from the nucleotide sequence set forth in SEQ ID NO:4 or SEQ ID NO:6 by virtue of the degeneracy of the genetic code are also encompassed by the present invention. Variations in the nucleotide sequence as set forth in SEQ ID NO:4 or SEQ ID NO:6 which are caused by point mutations or by induced modifications are also included in the invention.

The present invention also provides polynucleotides encoding homologues of the murine and human U4 from other animal species, particularly other mammalian species. Species homologues can be identified and isolated by making probes or primers from the murine or human sequences disclosed herein and screening a library from an appropriate species, such as for example libraries constructed from PBMCs, thymus or testis of the relevant species.

The isolated polynucleotides of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the U4 protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means enzymatically or chemically ligated to form a covalent bond between the isolated polynucleotide of the invention and the expression control sequence, in such a way that the U4 protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the U4 protein. Any cell type capable of expressing functional U4 protein may be used. Suitable mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal WO 99/53066 PCT/US99/07882 A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK, Rat2, BaF3, 32D, FDCP-1, PC12, Mix or C2C12 cells.

The U4 protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. Soluble forms of the U4 protein may also be produced in insect cells using appropriate isolated polynucleotides as described above.

Alternatively, the U4 protein may be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Suitable bacterial strains include Escherichia coli, Bacillus subtilis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins.

Expression in bacteria may result in formation of inclusion bodies incorporating the recombinant protein. Thus, refolding of the recombinant protein may be required in order to produce active or more active material. Several methods for obtaining correctly folded heterologous proteins from bacterial inclusion bodies are known in the art. These methods generally involve solubilizing the protein from the inclusion bodies, then denaturing the protein completely using a chaotropic agent. When cysteine residues are present in the primary amino acid sequence of the protein, it is often necessary to accomplish the refolding in an environment which allows correct formation of disulfide bonds (a redox system). General methods of refolding are disclosed in Kohno, Meth.

WO 99/53066 PCT/US99/07882 Enzym., 185:187-195 (1990). EP 0433225 and copending application USSN 08/163,877 describe other appropriate methods.

The U4 protein of the invention may also be expressed as a product of transgenic animals, as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a polynucleotide sequence encoding the U4 protein.

The U4 protein of the invention may be prepared by growing a culture transformed host cells under culture conditions necessary to express the desired protein. The resulting expressed protein may then be purified from the culture medium or cell extracts. Soluble forms of the U4 protein of the invention can be purified from conditioned media. Membrane-bound forms of U4 protein of the invention can be purified by preparing a total membrane fraction from the expressing cell and extracting the membranes with a non-ionic detergent such as Triton X-100.

The U4 protein can be purified using methods known to those skilled in the art. For example, the U4 protein of the invention can be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium.

Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) or polyetheyleneimine (PEI) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups. Sulfopropyl groups are preferred S-Sepharose® columns). The purification of the U4 protein from culture supernatant may also include one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography.

Finally, one or more reverse-phase high performance liquid chromatography (RP- WO 99/53066 PCT/US99/07882 HPLC) steps employing hydrophobic RP-HPLC media, silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the U4 protein. Affinity columns including antibodies to the U4 protein can also be used in purification in accordance with known methods. Some or all of the foregoing purification steps, in various combinations or with other known methods, can also be employed to provide a substantially purified isolated recombinant protein.

Preferably, the isolated U4 protein is purified so that it is substantially free of other mammalian proteins.

U4 proteins of the invention may also be used to screen for agents which are capable of binding to U4. Binding assays using a desired binding protein, immobilized or not, are well known in the art and may be used for this purpose using the U4 protein of the invention. Purified cell based or protein based (cell free) screening assays may be used to identify such agents. For example, U4 protein may be immobilized in purified form on a carrier and binding or potential ligands to purified U4 protein may be measured.

U4 proteins, purified from cells or recombinantly produced, may be used as a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may contain, in addition to U4 or inhibitor and carrier, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.

The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-14, IL- G-CSF, stem cell factor, and erythropoietin. The pharmaceutical composition may also include anti-cytokine antibodies. The pharmaceutical composition may contain thrombolytic or anti-thrombotic factors such as plasminogen activator and Factor VI. The pharmaceutical composition may further contain other antiinflammatory agents. Such additional factors and/or agents may be included in the WO 99/53066 PCT/US99/07882 pharmaceutical composition to produce a synergistic effect with isolated U4 protein, or to minimize side effects caused by the isolated U4 protein. Conversely, isolated U4 protein may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or antiinflammatory agent.

The pharmaceutical composition of the invention may be in the form of a liposome in which isolated U4 protein is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No.

4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, amelioration of symptoms of, healing of, or increase in rate of healing of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of isolated U4 protein is administered to a mammal. Isolated U4 protein may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors.

WO 99/53066 PCT/US99/07882 When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, U4 protein may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or antithrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering U4 protein in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of U4 protein used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of U4 protein is administered orally, U4 protein will be in the form of a tablet, capsule, powder, solution or elixir.

When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% U4 protein, and preferably from about 25 to 90% U4 protein. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of U4 protein, and preferably from about 1 to 50% U4 protein.

When a therapeutically effective amount of U4 protein is administered by intravenous, cutaneous or subcutaneous injection, U4 protein will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to U4 protein an isotonic vehicle such as Sodium Chloride Injection, WO 99/53066 PCT/US99/07882 Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additive known to those of skill in the art.

The amount of U4 protein in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of U4 protein with which to treat each individual patient. Initially, the attending physician will administer low doses of U4 protein and observe the patient's response. Larger doses of U4 protein may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not generally increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 pg to about 100 mg of U4 protein per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the U4 protein will be in the range of 12 to 24 hours of continuous intravenous administration.

Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

The polynucleotide and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Cvtokine and Cell Proliferation/Differentiation Activity WO 99/53066 PCT/US99/07882 A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods: Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H.

Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology.

J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon y, Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto.

1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto.

1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of WO 99/53066 PCT/US99/07882 human Interleukin 11 Bennett, Giannotti, Clark, S.C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 Ciarletta, Giannotti, Clark, S.C. and Turner, K.J. In Current Protocols in Immunology. J.E.e.a. Coligan eds.

Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun.

11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol.

140:508-512, 1988.

Immune Stimulating or Suppressing Activity A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the WO 99/53066 PCT/US99/07882 present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen B7- 1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a WO 99/53066 PCT/US99/07882 subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.

Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.

Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigenspecific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRLlpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis WO 99/53066 PCT/US99/07882 might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigenpulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.

For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of a cytoplasmic-domain truncated portion) of an MHC class I a chain protein and P 2 microglobulin protein or an MHC class II a chain protein and an MHC class II chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected WO 99/53066 PCT/US99/07882 tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.

Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1- 3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci.

USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol.

153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology.

J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Thi and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley- Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

WO 99/53066 PCT/US99/07882 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961- 965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelosuppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to WO 99/53066 PCT/US99/07882 platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation; aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells.

R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc.., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Research Uses and Utilities WO 99/53066 PCT/US99/07882 polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction.

Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: WO 99/53066 PCT/US99/07882 A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, E.F.

Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

U4 proteins of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the U4 protein and which may inhibit binding of ligands to the receptor. Such antibodies may be obtained using the entire U4 as an immunogen, or by using fragments of U4. Smaller fragments of the U4 may also be used to immunize animals. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Additional peptide immunogens may be generated by replacing tyrosine residues with sulfated tyrosine residues. Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J.Amer.Chem.Soc. 2149-2154 (1963); J.L. Krstenansky, et al., FEBS Lett. 211, 10 (1987).

Neutralizing or non-neutralizing antibodies (preferably monoclonal antibodies) binding to U4 protein may also be useful therapeutics for certain tumors and also in the treatment of conditions described above. These neutralizing monoclonal antibodies may be capable of blocking ligand binding to the U4 receptor chain.

Example Exnression of U4 Protein WO 99/53066 PCTIUS99/07882 DNA encoding the full-length murine U4 protein was fused to a spacer sequence encoding Gly-Ser-Gly by PCR and ligated in frame with sequences encoding the hinge CH2 CH3 regions of human IgGI in the COS-1 expression vector pED.Fc The DNA was transfected into Cos cells and expression of the fusion protein was detected by ELISA using antibodies that detected the IgGI portion of the protein. This demonstrated that the protein could be expressed and secreted in Cos cells.

All patent and literature references cited herein are incorporated by reference as if fully set forth.

EDITORIAL NOTE APPLICATION NUMBER 34889/99 The following Sequence Listing pages 1 to 10 are part of the description. The claims pages follow on pages "25" to "26".

WO 99/53066 PCT/US99/07882 SEQUENCE LISTING GENERAL INFORMATION: APPLICANT: Donaldson, Debra Collins, Mary Neben, Tamlyn Whitters, Matthew (ii) TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN (iii) NUMBER OF SEQUENCES: (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: Genetics Institute, Inc.

STREET: 87 CambridgePark Drive CITY: Cambridge STATE: MA COUNTRY: USA ZIP: 02140 COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release Version #1.25 (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE:

CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION: NAME: Brown, Scott A.

REGISTRATION NUMBER: 32,724 REFERENCE/DOCKET NUMBER: GI5287 (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: (617) 498-8224 TELEFAX: (617) 876-5851 INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 70 amino acids TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: YES (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: Leu Met Thr Asn Ala Phe Ile Ser Ile Ile Asp Asp Leu Ser Lys Tyr 1 5 10 Asp Val Gin Val Arg Ala Ala Val Ser Ser Met Cys Arg Glu Ala Gly 25 Leu Trp Ser Glu Trp Ser Gin Pro Ile Tyr Val Gly Asn Asp Glu His 40 WO 99/53066 PCT/US99/07882 Lys Pro Leu Arg Glu Trp Phe Val Ile Val Ile Met Ala Thr Ile Cys 55 Phe Ile Leu Leu Ile Leu INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid DESCRIPTION: /desc "probe" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: CTTGGCTTGG AAGAGGAAAT CCTTGAGAGC INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid DESCRIPTION: /desc "probe" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CTGAGCGTGC GCTGGGTGTC GCCAC INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 1656 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GTCGACCTTC GCTGTCCGCG CCCAGTGACG CGCGTGAGGA CCGCAGACTC GCCCCCGCCC CATACCGGCG TTGCAGTCAC CATGCCCGCG GGTCGCCCGG GCCCCGTCGC CCAATCCGCG GTCCTCGCTG TGGTCGCCTC TGTTGCTCTG TGTCCTCGGG AGCCCACACA GCTGTAATCA GCCCCCAGGA CCCCACCTTT AGCTACCTGC TCTATACATG GAGACACACC TGGGGCCACC

CCCGAGCCCC

CGCCCGTTGC

CGGCGGCCGC

GTGCCTCGGG

CTCATCGGCT

GCTGAGGGGC

AATCTGCACC

GCGCCACCCC

CGCGGCCGCT

GCGGATCGGG

CCTCCCTGCA

TCTACTGGAC

WO 99/53066

CCTCAATGGT

CCTGGCCCTG

CGCCCGAGAT

GCCTTTTAAC

GGGTGCACAC

GTACGGTCAG

CCCCAAGGAC

AGGCTCAGCA

CCCACCCGAC

GGTCTCACCA

CGTGGAGGAC

TCTCGCGGGC

GATCTATGGG

CACCCCTCGA

GCCCAGCTCG

CGCATACTGC

GTCACACAAG

GAGAGGTCCT

GGCTCACCTG

TGGGGCACAA

TACCCCAGTG

TAAAGGAGTT

PCTIUS99/07882

CGCCGCCTGC

GCTAACCTTA

GGCAGCATTC

ATCAGCTGCT

GGGGAGACAT

GATAACACAT

CTGGCCCTCT

AGATCTGATG

GTGCACGTGA

CCAGCTCTCA

AGCGTGGACT

CTGAAGCCCG

TCGAAAAAGG

AGTGAGCGCC

GGCCCGGTGC

TCGAACCTTA

ACCCGAAACC

GCCGGCTAAA

AATTGGAGCC

TGAGCTCCCA

TGGGTAGGGT

GTTCAGGTCC

CCTCTGAGCT

ATGGGTCCAG

TGGCTGGCTC

GGTCCCGGA.A

TCTTACATAC

GTGAGGAGTA

TCACTCCCTA

TCCTCACACT

GCCGCGTTGG

AGGATTTCCT

GGAAGGTGGT

GCACCGTTTA

CGGGAATCTG

CGGGCCCGGG

GGCGCGAGCT

GTTTCCGCCT

AGGACGAGGG

CTCTAAGGAT

CCTCTGTACC

CAACCACAGC

TGGGGTATTG

GTCCCGCCTC CTTAACACCT GCAGCAGTCA GGAGACAATC CTGCCTCTAT GTTGGCTTGC CATGAAGGAT CTCACGTGCC CAACTACTCC CTCAAGTACA CCACACTGTG GGCCCTCACT TGAGATCTGG GTGGAAGCCA

GGATGTCCTG

GGGCCTGGAG

CTTCCAAGCC

GGATGACGTC

CTTCGTCCAA

GAGCGAGTGG

CGGCGGGGTG

CAAGCAGTTC

GTACGACCAG

GATCCTGCCC

AGGCCATCCT

GACGTGGTGA

GACCAGCTGA

AAGTACCAGA

AGCAACCAGA

GTGCGTTGTA

AGCCACCCCA

TGCGAGCCGC

CTCGGCTGGC

TGGCGTGCTT

TCGGGCAGAC

CCTGCTGGGT

CCACCCTGGC

TGGTGTGTCA

CCCCTGAGAA

GCTGGACACC

AGCTGAGGTG

CATGCCATAT

CCAATCGCCT

CCACGGACCC

GTGTGCGCTG

TCCGCTACCG

CCTCCTGCCG

ACCCATTCGG

CCGCTGCCTC

GGGGCGGCGA

TCAAGAAGCA

GGATGCAGAA

GGGGTGCGGC

CAGACCTGGA

TACCAGAGGC

420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1656 ATCTGGGCAA CAAAGAAACC TTTGGTCCAC ATGATGGTCA CACTTGGATA CAGGGCCTCC CAAGAGTCTC TTTAAATAAA CGAAAAAAAA GTCGAC INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 425 amino acids TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) Met SEQUENCE DESCRIPTION: SEQ ID Pro Ala Gly Arg Pro Gly Pro Val Ala 10 Gin Ser Ala Arg Arg Pro Pro Arg Pro Leu Ser Ser Leu Trp Ser Pro Leu Leu Leu 25 Gly Val Pro Arg Gly Gly Ser Gly Ala His Thr Ala Val.

40 Cys Val Leu Ile Ser Pro Gln Asp Pro Thr Phe Leu Ile Gly Ser Ser Leu Gln Ala Thr Cys Ser WO 99/53066 WO 9953066PCTJUS99/07882 Ile His Gly Asp Thr Pro Gly Ala Thr Ala Glu 75 Leu Ser Ser Gly Ser 145 Giy Lys Val Pro Ser 225 Pro Ser Ala Val Lys 305 Ile Thr Vai Giu Asn 385 Ser Gly Arg Leu Ala 100 Asp Asn 115 Cys Leu Trp Ser His Giy Arg Trp 180 Pro His 195 Giu Ile Val Leu Asp Val Arg Trp 260 Tyr Gin 275 Asp Asp Gly Thr Gly Ser Ala Ser 340 Giu Pro 355 Lys Gin Ser Phe Lys Thr 70 Leu Ala Val Val Asn 150 Thr Giy Cys Val Leu 230 Val Ser Arg Ser Tyr 310 Lys Pro Giy Leu Leu 390 Asn Pro Leu Cys Gly 135 Met Phe Gin His Glu 215 Asp Ser Pro Tyr Asn 295 Phe Ala Arg Gly Gly 375 Tyr Gin Ser Ala His 120 Leu Lys Leu Asp Ile 200 Ala Val Arg Pro Arg 280 Gin Val Giy Ser Glu 360 Trp Asp Asp Glu Leu Ser Asn Leu Asn 105 Ala Arg Asp Pro Pro Giu Asp Leu Thr 155 His Thr Asn 170 Asn Thr Cys 185 Pro Lys Asp Thr Asn Arg Leu Asp Val 235 Val Gly Gly 250 Aia Leu Lys 265 Val Giu Asp Thr Ser Cys Gin Val Arg 315 Ile Trp Ser 330 Giu Arg Pro 345 Pro Ser Ser Leu Lys Lys Gin Trp Arg 395 Giti Gly Ile 410 Gly Arg Gly Gly Lys 140 Cys Tyr G lu Leu Leu 220 Val Leu Asp Ser Ar g 300 Cys Glu Gly Gly His 380 Leu Tyr Trp Leu Arg 110 Ile Phe Trp Leu Tyr 190 Leu Ser Thr Asp Leu 270 Asp Ala Pro Ser Gly 350 Val Tyr Asn Gin Leu Asn Thr Lys 175 His Phe Ala Asp Gin 255 Phe Trp Gly Phe His 335 Gly Arg Cys Thr Thr Gin Ala Ile Pro 160 Tyr Thr Thr Arg Pro 240 Leu Gin Lys Leu Gly 320 Pro Gly Arg Ser Lys 400 Ala Trp Met Gin Leu Pro Ser Gly Arg 415 405 Arg Gly Ala Ala Arg Gly Pro Aia Gly WO 99/53066 WO 9953066PCTIUS99/07882 INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 1579 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GCGGCCGCCG

CGGATCAGGA

CCGTTGCTGC

GCCCACACAG

CTCCCTGCTG GCCACCTGCT

CTACTGGACC

CACCTTGGCT

CGTGTGCCAC

CCCAGAGAAA

CTGGACGCCA

GCTTAGGTGG

CTGCCACATC

CAACCGCCTG

CACGGACCCC

CGTGCGCTGG

CCGCTACCGA

CTCCTGCCGC

CCCCTTTGGC

AGCCGCCTCC

GGGCGGAGAG

CAAGAAGCAC

GATGCAGAAG

GGGCACGGCG

GTGGAGACGC

CTGAGCCACC

GACTCCCACG

TTGGTTGAGT

CTCAACGGGC

CTGGCCCTGG

GCCCGTGACG

CCCGTCAACA

GGGGCCCACG

TATGGCCAGG

CCCAAGGACC

GGCTCTGCCC

CCGCCCGACG

GTGTCGCCAC

GTGGAGGACA

CTGGCCGGCC

ATCTATGGCT

ACTCCCCGCA

CCGAGCTCGG

GCGTACTGCT

TCGCACAAGA

AGAGGTCCTG

AGAGGCCGAA

CTCAGCAGGA

TGAGGCCACC

TGCCTAGAAC

CCCTGCTGCT

CTGTGATCAG

CAGTGCACGG

GCCGCCTGCC

CCAACCTCAA

GCAGCATCCT

TCAGCTGCTG

GGGAGACCTT

ACAACACATG

TGGCTCTCTT

GCTCCGATGT

TGCACGTGAG

CCGCCCTCAA

GTGTGGACTG

TGAAACCCGG

CCAAGAAAGC

GTGAGCGCCC

GGCCGGTGCG

CCAACCTCAG

CCCGCAACCA

CCAGATAAGC

CCCAAACTGG

GCTGGGGTGG

TTTGGGTGCA

CCCTGCCAGG

GCTGCTCTGC GTCCTCGGGG TCCCCAGGAT CCCACGCTTC AGACCCACCA GGAGCCACCG CCCTGAGCTC TCCCGTGTAC

TGGGTCCAGG

GGCTGGCTCC

GTCCAAGAAC

CCTCCACACC

TGAGGAGTAC

TACGCCCTAT

ACTCACGCTG

CCGCGTCGGG

GGATTTCCTC

GAAGGTGGTG

CACCGTGTAC

CGGGATCTGG

GGGCCCGGGC

GCGCGAGCTC

CTTCCGCCTC

GGACGAGGGG

TGTAGGGGCT

GGCCACCTCT

CCCCTGAGCT

CCCCAGTGGG

GCTGGGGGTG

CAGCGGTCGG

TGCCTCTATG

ATGAAGGACT

AACTACTCCC

CACACAGTGG

GAGATCTGGG

GATATCCTGG

GGCCTGGAGG

TTTCAAGCCA

GACGATGTGA

TTCGTGCAAG

AGTGAGTGGA

GGCGGGGCGT

AAGCAGTTCC

TACGACCAGT

ATCCTGC!CCT

CAGGCCACCC

GTACCCTCAC

CCAACGGCCA

TGTGTGTGTG

AGAAGGGGAG

CGCCGCGAGC

TCATCGGCTC

CCGAGGGCCT

TCAACGCCTC

GGGACAACCT

TTGGCCTGCC

TGACCTGCCG

TCAAGTACAA

GGCCCCACTC

TGGAGGCCAC

ATGTGGTGAC

ACCAGCTGAG

AATACCAGAT

GCAACCAGAC

TGCGCTGCAA

GCCACCCCAC

GCGAACCGCG

TGGGCTGGCT

GGCGAGCCTG

CGGGCAGACG

TCCCTGCCAC

TTCAGGGCAC

TAACAGCTCT

TGTGTGAGGG

TCATTACTCC

120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 CCATTACCTA GGGCCCCTCC AAAAGAGTCC TTTTAAATAA. ATGAGCTATT TAGGTGCTGT WO 99/53066 GAAAAAAAAA AAAAAAAAA INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 408 amino acids TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: PCT/US99/07882 1579 Arg Pro Pro Pro Leu Leu Pro Leu Leu Leu Leu Leu Cys Val Leu Gly Ala Asp His Asn Thr Gly Ser Cys Ala 145 Leu Gly Tyr Asp Pro 225 Val Lys Pro Arg Pro Thr Gly Asp Gly Arg Leu Ala Asp Asn Cys Leu 115 Trp Ser 130 His Gly Arg Trp Pro His Giu Ile 195 Val Leu 210 Asp Val Arg Trp Tyr Gin Ala Leu Pro Arg Leu Leu 100 Tyr Lys Giu Tyr Ser 180 Trp Thr His Val Ile Ser Ile Giy Pro 70 Leu Cys Gly Met Phe 150 Gin His Giu Asp Ser 230 Pro Tyr Ala Leu Gly Arg .75 Gly Gly Lys Cys Tyr 155 Giu Leu Leu Val Leu 235 Asp Ser Val Ala Leu Val Ser Ser Pro Arg 140 Ser Giu Ala Gly Thr 220 Giu Phe Val Ser Pro Gin Cys Ser Val Trp Thr Leu Asn Ala Ser Gin Arg Ser Leu Ala Giy 110 Asn Ile Ser Thr Pro Gly Lys Tyr Lys 160 His Thr Vai 175 Phe Thr Pro 190 Ala Arg Ser Asp Pro Pro Gin Leu Ser 240 Phe Gin Ala 255 Trp Lys Vai 270 260 265 Val Asp Asp Val Ser Asn Gin Thr Ser Cys Arg Leu Ala Gly Leu Lys WO 99/53066 PCT/US99/07882 Pro Gly 290 Tyr Gly Thr Val Tyr Phe Val Arg Cys Asn 300 Trp Phe Gly Ile Ser Lys Lys Ile Trp Ser Ser His Pro Ala Ser Thr Ser Glu Arg Pro Gly Gly Gly Ala 335 Cys Glu Pro Leu Lys Gin 355 Leu Ser Phe Gly Glu Pro Gly Pro Val Leu Gly Trp Lys His Ala Arg Arg Glu 350 Cys Ser Asn Gin Lys Ser Arg Leu Tyr Trp Arg Ala 370 His Lys Trp 380 Pro Thr Arg Asn Gin Asp Glu Gly Ile 390 Pro Ala Arg Ser Gly Arg Thr Ala Arg INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS: LENGTH: 14 amino acids TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Pro Ala Gly Arg Pro Gly Pro Val Ala Asn Ser Ala Arg 1 5 INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 1787 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GAATTCCGGC GCGTCCGCGC CCAGCGACGT GCGGGCGGCC CCGGCCTGCG TCCCGCGCCC TGCGCCACCG CCGCCGAGCC GGCAGCGCCG GCCCCATGCC CGCCGGCCGC CGGGGCCCCG CCGCCGCCGT TGCTGCCCCT GCTGCTGCTG CTCTGCGTCC TCAGGAGCCC ACACAGCTGT GATCAGTCCC CAGGATCCCA TGGCCCGCGC CCTCCCGCGC GCAGCCCGCC GCGCGCCCCC CCGCCCAATC CGCGCGGCGG TCGGGGCGCC GCGAGCCGGA CGCTTCTCAT CGGCTCCTCC WO 99/53066 WO 9953066PCTIUS99/07882

CTGCTGGCCA

TGGACCCTCA

TTGGCTCTGG

TGCCACGCCC

GAGAAACCCG

ACGCCAGGGG

AGGTGGTATG

CACATCCCCA

CGCCTGGGCT

GACCCCCCGC

CGCTGGGTGT

TACCGAGTGG

TGCCGCCTGG

TTTGGCATCT

GCCTCCACTC

GGAGAGCCGA

AAGCACGCGT

CAGAAGTCGC

ACGGCGAGAG

AGACGCAGAG

GCCACCCTCA

CCCACGTGAG

TTGAGTTGCC

TACCTAGGGC

CCTGCTCAGT

ACGGGCGCCG

CCCTGGCCAA

GTGACGGCAG

TCAACATCAG

CCCACGGGGA

GCCAGGACAA

AGGACCTGGC

CTGCCCGCTC

CCGACGTGCA

CGCCACCCGC

AGGACAGTGT

CCGGCCTGAA

ATGGCTCCAA

CCCGCAGTGA

GCTCGGGGCC

ACTGCTCCAA

ACAAGACCCG

GTCCTGCCAG

GCCGAACCCA

GCAGGAGCTG

GCCACCTTTG

TAGAACCCCT

CCCTCCAAAA

GCACGGAGAC

CCTGCCCCCT

CCTCAATGGG

CATCCTGGCT

CTGCTGGTCC

GACCTTCCTC

CACATGTGAG

TCTCTTTACG

CGATGTACTC

CGTGAGCCGC

CCTCAAGGAT

GGACTGGAAG

ACCCGGCACC

GAAAGCCGGG

GCGCCCGGGC

GGTGCGGCGC

CCTCAGCTTC

CAACCAGGAC

ATAAGCTGTA

AACTGGGGCC

GGGTGGCCCC

GGTGCACCCC

GCCAGGGCTG

GAGTCCTTTT

CCACCAGGAG

GAGCTCTCCC

TCCAGGCAGC

GGCTCCTGCC

AAGAACATGA

CACACCAACT

GAGTACCACA

CCCTATGAGA

ACGCTGGATA

GTCGGGGGCC

TTCCTCTTTC

GTGGTGGACG

GTGTACTTCG

ATCTGGAGTG

CCGGGCGGCG

GAGCTCAAGC

CGCCTCTACG

GAGGGGATCC

GGGGCTCAGG

ACCTCTGTAC

TGAGCTCCAA

AGTGGGTGTG

GGGGTGAGAA

AAATAAATGA

CCACCGCCGA

GTGTACTCAA

GGTCGGGGGA

TCTATGTTGG

AGGACTTGAC

ACTCCCTCAA

CAGTGGGGCC

TCTGGGTGGA

TCCTGGATGT

TGGAGGACCA

AAGCCAAATA

ATGTGAGCAA

TGCAAGTGCG

AGTGGAGCCA

GGGCGTGCGA

AGTTCCTGGG

ACCAGTGGCG

TGCCCTCGGG

CCACCCTCCC

CCTCACTTCA

CGGCCATAAC

TGTGTGTGTG

GGGGAGTCAT

GCTATTTAGG

GGGCCTCTAC

CGCCTCCACC

CAACCTCGTG

CCTGCCCCCA

CTGCCGCTGG

GTACAAGCTT

CCACTCCTGC

GGCCACCAAC

GGTGACCACG

GCTGAGCGTG

CCAGATCCGC

CCAGACCTCC

CTGCAACCCC

CCCCACAGCC

ACCGCGGGGC

CTGGCTCAAG

AGCCTGGATG

CAGACGGGGC

TGCCACGTGG

GGGCACCTGA

AGCTCTGACT

TGAGGGTTGG

TACTCCCCAT

TGCAAAAAAA

360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1787 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAACC INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 422 amino acids TYPE: amino acid

STRANDEDNESS:

TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID Met Pro Ala Gly Arg Arg Gly Pro Ala Ala Gin Ser Ala Arg Arg Pro 1 5 10 Pro Pro Leu Leu Pro Leu Leu Leu Leu Leu Cys Val Leu Gly Ala Pro WO 99/53066 WO 9953066PCT[US99/07882 Gin Asp Pro Arg Ala Gly Ser Gly Ala Hius Thr Ala Val Ile Ser Pro Leu Leu Giu Gly Ser Arg Asn Gly 105 Asp Giy 120 Glu Lys Thr Cys Asn Tyr Cys Giu 185 Asp Leu 200 Arg Leu Val Val Gly Leu Lys Asp 265 Asp Ser 280 Cys Arg Arg Cys Ser Giu Pro Giy 345 Ser Gly 360 Lys His Al a Leu Val Ser Ser Pro Arg Ser 170 Giu Ala Gly Thr Glu 250 Phe Val Leu Asn Trp 330 Pro Pro Ala Thr Cys Tyr Trp Leu Asn Arg Gin Ile Leu Val Asn 140 Trp, Thr 155 Leu Lys Tyr His Leu Phe Ser Ala 220 Thr Asp 235 Asp Gin Leu Phe Asp Trp Ala Gly 300 Pro Phe 315 Ser His Gly Gly Val Arg Tyr Cys 380 Phe Arg Leu Tyr Asp Gln Trp Arg Ala Trp Met Gin Lys Ser His Lys WO 99/53066 PCTIUS99/07882 385 390 395 400 Thr Arg Asn Gin Asp Glu Gly Ile Leu Pro Ser Giy Arg Arg Giy Thr 405 410 415 Ala Arg Gly Pro Ala Arg 420

Claims (13)

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: the nucleotide sequence SEQ ID NO:9 from nucleotide 136 to nucleotide 1401; a nucleotide sequence varying form the sequence of the nucleotide sequence specified in as a result of degeneracy of the generic code; and an allelic variant of the nucleotide sequence specified in

2. The polynucleotide of claim 1 wherein said nucleotide sequence encodes for a protein having a biological activity of the U4 hematopoietin receptor superfamily chain.

3. The polynucleotide of claim 1 or claim 2 wherein said nucleotide sequence is operably linked to an expression control sequence.

4. A host cell transformed with the polynucleotide of claim 3. The host cell of claim 4, wherein said cell is a mammalian cell.

6. A process for producing a U4 protein, said process comprising; growing a culture of the host cell of claim 4 a suitable culture medium; and purifying the U4 protein from the culture. 25 7. An isolated U4 protein comprising the amino acid sequence of SEQ ID

8. A pharmaceutical composition comprising a protein of claim 7 and a pharmaceutically acceptable carrier.

9. A protein produced according to the process of claim 6. The protein of claim 7 wherein said amino acid sequence is part of a fusion 9 protein. 9 9 9 COMS ID No: SMBI-00488587 Received by IP Australia: Time 09:43 Date 2003-11-11 r 11/11 '03 08:431FA 3 9663 3099 FB RICE CU.' 26

11. The protein of claim 10 comprising an Fe fragment.

12. The nucleic acid of claim 1 comprising SEQ ID NO:9 from nucleotide 136 to nucleotide 1401.

13. An isolated polynucleotide according to any one of claims 1 to 3 or 12 substantially as hereinbefore described with particular reference to the example and/or the preferred embodiments.

14. A host cell according to claim 4 or 5 substantially as hereinbefore described with particular reference to the example and/or the preferred embodiments. A process for producing a U4 protein according to claim 6 substantially as hereinbefore described with particular reference to the example and/or the preferred embodiments.

16. A pharmaceutical composition according to claim 8 substantially as hereinbefore described with particular reference to the example and/or the preferred embodiments.

17. A protein according to any one of claims 7 or 9 to 11 substantially as Shereinbefore described with particular reference to the example and/or the preferred embodiments. Dated this tenth day of November 2003 Genetics Institute, LLC Patent Attorneys for the Applicant F B RICE CO e* e *•e *ee 006 COMS ID No: SMBI-00488587 Received by IP Australia: Time 09:43 Date 2003-11-11